Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 6
2005 5
2006 4
2007 2
2008 6
2009 10
2010 9
2011 9
2012 8
2013 10
2014 6
2015 14
2016 17
2017 18
2018 21
2019 23
2020 26
2021 23
2022 17
2023 26
2024 11
2025 13
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Among authors: toffoli g. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Idarubicin.
Crivellari D, Toffoli G, Lombardi D, Berretta M, Sorio R, Magri MD, Spazzapan S, Scuderi C, Veronesi A. Crivellari D, et al. Among authors: toffoli g. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S73-4. doi: 10.1177/030089160208800122. Tumori. 2002. PMID: 11989932 No abstract available.
Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study.
Guchelaar HJ, van der Wouden CH, Manson LEN, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cecchin E, Cheung KC, Deneer VHM, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila-Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Swen JJ; Ubiquitous Pharmacogenomics Consortium. Guchelaar HJ, et al. Among authors: toffoli g. Clin Pharmacol Ther. 2025 Oct;118(4):803-812. doi: 10.1002/cpt.3749. Epub 2025 Jun 24. Clin Pharmacol Ther. 2025. PMID: 40552566 Free PMC article.
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L, Guardascione M, D'Andrea M, Favaretto A, Puglisi F, Swen JJ, Guchelaar HJ, Toffoli G, Cecchin E. Roncato R, et al. Among authors: toffoli g. JAMA Netw Open. 2024 Dec 2;7(12):e2449441. doi: 10.1001/jamanetworkopen.2024.49441. JAMA Netw Open. 2024. PMID: 39641926 Free PMC article. Clinical Trial.
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.
De Mattia E, Park Y, Peruzzi E, Zhou Y, Roncato R, Polesel J, Scarabel L, Schwab M, Guchelaar HJ, Swen JJ, Spina M, Puglisi F, Toffoli G, Lauschke VM, Cecchin E. De Mattia E, et al. Among authors: toffoli g. Oncogene. 2025 Nov;44(45):4352-4362. doi: 10.1038/s41388-025-03587-7. Epub 2025 Sep 25. Oncogene. 2025. PMID: 40999005 Clinical Trial.
Anti-HER2 Super Stealth Immunoliposomes for Targeted-Chemotherapy.
Canato E, Grigoletto A, Zanotto I, Tedeschini T, Campara B, Quaglio G, Toffoli G, Mandracchia D, Dinarello A, Tiso N, Argenton F, Sayaf K, Guido M, Gabbia D, De Martin S, Pasut G. Canato E, et al. Among authors: toffoli g. Adv Healthc Mater. 2023 Nov;12(29):e2301650. doi: 10.1002/adhm.202301650. Epub 2023 Aug 30. Adv Healthc Mater. 2023. PMID: 37590033 Free PMC article.
DNA Nanotechnology for Cancer Therapy.
Kumar V, Palazzolo S, Bayda S, Corona G, Toffoli G, Rizzolio F. Kumar V, et al. Among authors: toffoli g. Theranostics. 2016 Mar 20;6(5):710-25. doi: 10.7150/thno.14203. eCollection 2016. Theranostics. 2016. PMID: 27022418 Free PMC article. Review.
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study.
Fragoulakis V, Swen JJ, Koufaki MI, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VHM, Dupui M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Manson LEN, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, van der Wouden CH, Dávila-Fajardo CL, Dolžan V, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ, Patrinos GP, Mitropoulou C. Fragoulakis V, et al. Among authors: toffoli g. EClinicalMedicine. 2025 Dec 16;91:103686. doi: 10.1016/j.eclinm.2025.103686. eCollection 2026 Jan. EClinicalMedicine. 2025. PMID: 41502919 Free PMC article.
Sarcomas and pharmacogenetics.
Biason P, Toffoli G. Biason P, et al. Among authors: toffoli g. Pharmacogenomics. 2005 Sep;6(6):585-601. doi: 10.2217/14622416.6.6.585. Pharmacogenomics. 2005. PMID: 16142999 Review.
267 results